Effects of Yishenbupi (tonifying-kidney and invigorating-spleen) prescription on the expression of renal fibrosis-associated proteins in unilateral ureteral occlusion rats
Journal Title: TMR Integrative Medicine - Year 2020, Vol 4, Issue 13
Abstract
Objective: To evaluate the effects and mechanism of the Yishenbupi (tonifying-kidney and invigorating-spleen) prescription on the expression of renal fibrosis-associated vimentin, α-SMA, and fibronectin in unilateral ureteral occlusion rats. Methods: A total of 48 SD (Sprague-Dawley) rats were randomly divided into the model, sham-operated (sham), irbesartan, and Yishenbupi groups, with 12 rats in each group. After the unilateral ureteral occlusion model was established, rats in the model and sham groups were administered normal saline, whereas rats in the Yishenbupi group were administered Yishenbupi prescription (18 g/kg/d) intragastrically and those in the irbesartan group were administered irbesartan (10 mg/kg/d) intragastrically. All rats were sacrificed 21 days later. Pathological changes in rat renal tissue were evaluated by H&E staining. The expression of vimentin, α-SMA, and fibronectin in renal tissues was detected by western blotting. Results: Compared with the sham group the model group had renal tubular epithelial cell atrophy, inflammatory cell infiltration accompanied with the proliferation of interstitial collagen fibers, fewer glomeruli, or glomerulosclerosis. Compared with the model group, significantly less renal tubular and glomerular damages, inflammatory cell infiltration, and collagen fibers were observed in different intervention groups, especially in the Yishenbupi group. Compared with the sham group, significantly higher expressions of fibrosis markers, including vimentin, α-SMA, and fibronectin, were observed in the model group. Compared with the model group, the expression of anti-fibrosis markers, including vimentin, α-SMA and fibronectin, was significantly decreased in both the irbesartan and Yishenbupi groups (P < 0.01); however, the Yishenbupi group showed higher efficacy than the irbesartan group (P < 0.05). Conclusion: The Yishenbupi prescription may improve renal fibrosis by reducing the expression of fibrosis-associated vimentin, α-SMA, and fibronectin.
Authors and Affiliations
Jue-Ying Chen,Ji-Wei Qiu,Jun-Lin Mo,Chun-Li Long,Wei Shi,Yong-Xiang Xie
Keywords
Related Articles
- EP ID EP689647
- DOI 10.12032/TMRIM202004013
- Views 187
- Downloads 0
Assessing people at risk of developing type 2 diabetes in Freetown, Sierra Leone
Objective: This study aims to estimate the proportion of adults that are at high risk of developing Type 2 diabetes mellitus, and to investigate the association of participants at high risk for developing diabetes with v...
The inhibitory effects of Yigan Jiangzhi formula on hepatic metastasis of colorectal cancer
Background: To observe the inhibitory effects of Yigan Jiangzhi formula (liver-supplementing lipid-lowering formula, YGJZF) on hepatic metastasis of colorectal cancer. Methods: The hepatic metastasis BALB-c mice model of...
Antioxidative effect of peroxiredoxin-3 in the rat myocardium exposed to renal ischemia-reperfusion injury
Background: Peroxiredoxin-3 (Prx-3) is known to be involved in the clearance of cellular hydrogen peroxide and plays an important role in protecting the myocardial tissue against damage of oxidative stress. However, the...
Research on potential of Cinnamomum cassia to be developed into supplemental food in prevention and treatment of diabetes
Objective: To dig out potential of Cinnamomum cassia Presl to be developed into health tonics in regulating blood glucose from effectiveness and marketing, we designed this research. Methods: We searched from PubChem, CN...
Combination of nutritional ketosis and hyperoxygenation therapy—promising ground for integrative cancer treatment: a systematic review
Though the cancer is a multifactorial disease, where various types of cancers exhibit varying mechanisms, pathways, genetic and cellular defects, the study of tumor micro-environment confirms that upregulated glycolysis...